semaj83/ctmatch_classification huggingface dataset:
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 16.0-23.0,  HPV Cervical Cancer Premalignancy Anogenital Warts Lifetime history of 0-4 sexual partners  History of abnormal PAP test or abnormal cervical biopsy result; history of external genital/vaginal warts; history of positive HPV test
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-30.0,  Healthy Female through 30 years of age (must not have reached the 31st birthday) Unless previously surgically sterilized, agrees to use an effective method of birth control (e.g., abstinence, intrauterine contraceptive device, oral contraceptives, diaphragm or condom in combination with contraceptive jelly, cream or foam, Norplant® or DepoProvera®) beginning 30 days before the first study injection and continuing through 60 days after the final study injection Healthy by medical history and physical examination Cervical specimen positive for HPV-16 and/or HPV-18 DNA using the Digene Hybrid Capture® II HPV test within 21 days of study entry Cervical cytology by Pap smear that is either normal or no greater than ASCUS or AGCUS, using the Cytyc ThinPrep® Pap Test, within 21 days of study entry (a normal Pap smear must also be adequate for interpretation; a Pap smear that is normal but inadequate for interpretation must be repeated). Those volunteers with ASCUS or AGCUS must have had a clinical evaluation by colposcopy within the previous month which showed no evidence of CIN or SIL No evidence of anogenital HPV lesions or no physical findings suggestive of other gynecologic pathogens on pelvic examination within 21 days of study entry Agrees to no other experimental therapy or vaccines until 30 days after the last study injection Written informed consent obtained from the volunteer  Acute illness or fever (oral temperature ³99.5°F [37.5°C]) at start of the study History or clinical manifestations of significant medical or psychiatric disorder Pregnant or lactating Use of immunosuppressive medication (inhaled and topical corticosteroids are permitted) within the previous 90 days or history of immunodeficiency History of cancer History of alcohol or drug abuse within the past 2 years At screening (must be within 21 days of study entry) any of the following: hemoglobin <11 gm/dL; white blood cell count <4000/mm3; platelet count <120,000/mm3; AST, ALT, creatinine >1.5x upper limit of normal for the laboratory in question; other abnormal laboratory values in the screening panel which in the opinion of the principal investigator are judged to be clinically significant Receipt of immunoglobulin or blood products within 90 days prior to study entry History of Pap smear more severe than ASCUS or AGCUS Positive tests for hepatitis C antibody, hepatitis B surface antigen, or HIV-1 antibody
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Papilloma Virus, Human Abnormal pap smear ASCUS or higher Age 18-postmenopausal  Less than 18 years old Prior hysterectomy Pregnancy Use of corticosteroids HIV positive
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Pregnancy Potential subjects must Be healthy women, who are sexually active, at risk for pregnancy and desiring contraception Be within the age range of 18 through 40 years inclusive Be at low-risk for human immunodeficiency virus (HIV) or sexually transmitted disease (STD) infection and currently have a single sex partner (minimum 4 months) who is also at low-risk for HIV or STD Have a negative urine pregnancy test prior to enrollment Have normal cyclic menses with a usual length of 24 to 35 days over the last 2 cycles or at least one spontaneous, normal menstrual cycle (2 menses) since delivery, abortion, or after discontinuing hormonal contraception/hormonal therapy Be willing to accept a risk of pregnancy Be willing to engage in at least 4 acts of heterosexual vaginal intercourse per month for a period of 6 months Be willing to be randomized to either study treatment Be willing to only use the study product as the primary method of contraception over the course of the study with the exception of emergency contraception (EC), when indicated  Potential subjects must not Have a history of allergy or sensitivity to spermicides or products containing N-9 Have had 3 or more urinary tract infections (UTI) in the past year Have UTI by urine culture or symptomatic yeast vaginitis or symptomatic bacterial vaginosis diagnosed by wet mount unless treated and proof of cure is documented Be pregnant, have a suspected pregnancy or desire to become pregnant during the course of the study Have a history of infertility or of conditions that may lead to infertility, without subsequent intrauterine pregnancy Have any contraindications to pregnancy (medical condition) or chronic use of category D or X medications Have had more than one sexual partner in the last 4 months Have shared injection drug needles within the past 12 months Have or have been suspected to have HIV infection
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Intraepithelial Neoplasia Uterine Cervical Dysplasia Patients may be enrolled in the study only if they meet all of the following years of age or older The patient or her authorized representative must sign and date an Ethical Review Board-approved informed consent document. All aspects of the protocol must be explained and written informed consent obtained Patients must have histological proof of HSIL (CIN 2/3) disease documented Cervical swabs must test positive for HPV (by Hybrid Capture 2) Patients must have a Hb ≥ 9 g/dl, a peripheral WBC ≥ 3000 mm3 and platelet counts ≥ 100,000 mm3 Normal hepatic and renal functions AST and ALT < 2.5 x ULN and creatinine < 1.5 x ULN, respectively Females of childbearing potential must use one of the following birth control methods during the treatment period and 2 weeks thereafter: oral, implantable, injectable contraceptives; abstinence (celibacy). Contraceptive sponges, IUD, spermicides, sponges, condoms, or partner's vasectomy are not acceptable methods of birth control  Patients will be excluded from the study for any of the following preexisting reasons Patients with LSIL (CIN 1) or invasive squamous cell carcinoma (SCC) SIL (CIN) involving the endocervix as determined by endocervical curettage, or otherwise not amenable to adequate colposcopic follow-up evaluations, i.e. unsatisfactory colposcopy CIN 3 involving more than two cervical quadrants on colposcopy Patients treated for cervical SIL within the past year Patients with other malignancy (except for non-melanoma skin) within the past 5 years Patients with any active infections (including HIV) other than HPV Patients with known clinically relevant immunological deficiency Concurrent treatment with cytotoxic, radiation, or immuno-stimulative therapy, or with systemic corticosteroids at a dose of > 5 mg/d of prednisone (or its equivalent) Participation in another investigational medication trial concurrently or within 30 days, or prior participation in an HPV vaccine trial. Treatment within the last 30 days with a medication that has not received regulatory approval at the time of study entry
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Cervical Intraepithelial Neoplasia Grade 1 Human Papilloma Virus Infection Histologically confirmed cervical intraepithelial neoplasia 1 (CIN 1) AND oncogenic human papillomavirus (HPV) positivity At increased risk for developing cervical cancer due to >= 1 of the following (documented 6-12 months ago)* Positive oncogenic HPV on DNA hybrid capture Low-grade squamous intraepithelial lesion cytology Histopathologically documented CIN 1 on cervical biopsy [Note: *Patients must now have current CIN 1 by histology or colposcopy AND HPV positivity] Cervical dysplasia by colposcopy OR positive biopsy No invasive cervical cancer or high-grade intraepithelial neoplasia on cervical biopsy or endocervical curettage ECOG performance status < 2 Total bilirubin < 2 times upper limit of normal (ULN) AST < 2 times ULN
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Oral Erosive Lichen Planus Confirmation of the diagnosis of OELP by histological examination and a clinical score superior to 3  Patients under 18 years Pregnancy or breast feeding Malignancy Severe or recurrent infections Uncontrolled chronic disorders Congenital or acquired immunosuppression and concomitant treatments potentially effective on OELP such as antimalarials, oral retinoids, steroids or immunosuppressive drugs
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-120.0,  Cervical Cancer Cervical Intraepithelial Neoplasia CIN All women who are referred for cervical colposcopy to the University of Oklahoma will be considered eligible for the study. These women will be categorized into four groups: (i) cancer, (ii) precancer, (iii) HPV-infected, and (iv) normal. Cancers will be limited to women diagnosed with early cancer (Stage 1-2) to minimize potential disease effects. Precancers will be defined as women diagnosed histologically with cervical intraepithelial neoplasia 3 (CIN3). This is a highly specific and well-reproduced diagnosis which effectively represents carcinoma in situ. All women testing DNA positive for any of the 13 known oncogenic HPV types (HPV-infected), but not diagnosed with CIN3 or cancer (all stages) will be placed in the HPV-positive group. This group will therefore encompass all HPV-infected women diagnosed with either cervical intraepithelial neoplasia 1 (CIN1), CIN2, low grade squamous intraepithelial lesion (LSIL), atypical squamous cells of undetermined significance (ASCUS), atypical glandular cells of underdetermined significance (AGUS), or found cytologically normal. Women referred to the colposcopy clinic but found to be negative for oncogenic HPV and normal upon histological diagnoses will be eligible as normal controls; this approach will be an ethical method for collecting biopsies from essentially "normal" women as there are many benign "look alike" conditions that are ruled out in colposcopy clinics. While this group may not be a random sample of the general population, the use of specimens from these women as controls will ensure a group of women who are truly confirmed as having no neoplasia  Women attending the clinic solely for vaginal colposcopies will be excluded from the study. Women who are under 18 years of age or pregnant at the visit will also be excluded from the study. In addition, women who have had prior treatment (women coming to the clinic for a follow-up visit subsequent to treatment (women coming to the clinic for a follow-up visit subsequent to treatment or women coming for their initial clinic visit following pretreatment with chemotherapy or radiation) will be excluded. All women with known HIV or AIDS will be excluded from the study. This information will not be readily available unless the woman has previously been seen at the University of Oklahoma clinic. This event is considered rare; recent studies of HIV and AIDS by the University of Oklahoma from the same population have been terminated due to the lack of HIV/AIDS detected in the population
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Cervical Neoplasia FOR PHASE OF STUDY: Less than 35 years of age. Intact uterus (non-hysterectomized). In good general health. Non-pregnant. For women not using OCs: Having regular cycles [cycles 25-35 days in length]. HPV16 seropositive [based on data from latest visit tested]. No evidence of HSIL/cancer [based on data from latest visit within cohort]. Willing to participate [informed consent]. FOR PHASE OF STUDY: Must be between the ages of 45 to 70 years. Women who do not have a final diagnosis of HSIL
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  HPV Women age 21 and older Non-pregnant, non-hysterectomized  Pregnant women and women under the age of 21 will not be included in this study
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Intraepithelial Neoplasia Grade 1 (CIN 1) Responsible women > 18 years with histologically proven CIN 1
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 16.0-23.0,  Papillomavirus Infections Genital Diseases, Female Healthy females 16 to 23 years of age Not pregnant at enrollment and must have agreed to use effective contraception through Month 7 of the study Lifetime history of 0 to 4 male sexual partners (individuals with whom penetrative sexual intercourse occurred)  No prior receipt of an Human Papillomavirus (HPV) vaccine No receipt of inactivated or recombinant vaccines within 14 days prior to enrollment or receipt of live vaccines within 21 days prior to enrollment No prior abnormal Pap test showing squamous intraepithelial lesion (SIL) or biopsy showing cervical intraepithelial neoplasia (CIN) No prior history of genital warts or treatment for genital warts
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Cervical Dysplasia cervical intraepithelial neoplasia II or III negative endocervical curettage not pregnant cervical conization is part of treatment plan  positive endocervical curettage pregnant medically unable to undergo surgery
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 21.0-100.0,  Cervical Neoplasia Women in KPNC aged 25 years or older who tested positive for HPV. Will also a random sample of women who tested negative for HPV  Male. Children under 18
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 26.0-65.0,  Cervical Intraepithelial Neoplasia Five-hundred women attending colposcopy and 500 women receiving cytology screening, including 250 unscreened women, will be recruited for the study. Non-pregnant, non-hysterectomized women aged 26-65 will be recruited  Women under 26 or over 65 years of age. Pregnant women or women having given birth to a child in the past 8 weeks. To insure women included in the study are not pregnant, we will ask women during the consenting process if they are pregnant. Women who answer yes for either query will be excluded. Participants will also receive a reminder call for their 2-week self-collection. At that time, women again will be asked if they are pregnant. If any woman answers yes, she will be instructed to not self-collect. Women who have had a total hysterectomy. Women who have an overt cancerous lesion visible upon exam by the clinician. Other reasons to women the inability to speak English, the appearance of mental incompetence, or refusal to participate or sign the informed consent form
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Precancerous Condition Underwent Pap smear, human papillomavirus (HPV) testing, and HIV testing AND meets any of the following Biopsy and colposcopy confirmed cervical intraepithelial neoplasia (CIN) or invasive cervical cancer (ICC), meeting any of the following CIN grade 2-3 or higher Repeated CIN1 (times 6) Abnormal Pap smear (atypical squamous cells of undetermined significance [ASCUS] or worse) HIV seropositive Negative cytology but positive for high-risk human papillomavirus (HPV) Negative cytology and negative HPV HIV negative (without biopsy-proven CIN 3 or worse) and high-risk HPV infection (types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 55, 56, 58, 59, 68, 82, 83, 73) >= 18 years of age  < 18 years of age Pregnant at screening Cervix not intact not able to provide informed consent
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cervical Cancer Precancerous Condition First mildly dyskaryotic Pap smear or a second borderline Pap smear taken within the Cervical Screening Wales program Patients under surveillance following treatment for high-grade cervical intraepithelial neoplasia are not eligible No clinical suspicion of a concurrent invasive cervical cancer No invasive cancer within the past 3 years No known HIV positivity Not pregnant or nursing Not planning to become pregnant within the next 6 months PRIOR No concurrent immunosuppressive drugs, warfarin, or theophylline No concurrent proton pump inhibitor drugs for ulcer or reflux disease (i.e., rabeprazole, esomeprazole magnesium, lansoprazole, omeprazole, or pantoprazole sodium)
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Cervical Cancer Abnormal Pap smear findings indicating the need for further treatment at the colposcopy clinic Scheduled for colposcopy at the Comprehensive Cancer Center of Wake Forest University No history of invasive cervical cancer Must be of Hispanic background, including any of the following Hispanic Latino Chicano Mexican American Puerto Rican Cuban American PRIOR
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Patients 18 years and older Non-pregnant Patients with abnormal smears with cervical intraepithelial neoplasia (both low grade squamous intraepithelial lesions and high grade squamous intraepithelial lesions equal to cervical intraepithelial neoplasia 1-3)  Patients who have had cytotoxic chemotherapy within 12-months prior to enrolling in this study, since the chemotherapy often induces change in the cervix